<DOC>
	<DOCNO>NCT00195481</DOCNO>
	<brief_summary>To determine safety sirolimus tablet renal allograft recipient postmarketing surveillance setting .</brief_summary>
	<brief_title>Study Evaluating Sirolimus Kidney Transplant Recipients India</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients End Stage Renal Disease 13 year age weigh 40 kilogram . Patients schedule receive kidney cadaveric donor , live unrelated donor living relate donor . Evidence major infection time sirolimus administration Use investigational drug treatment 4 week prior enrol study treatment phase . Females pregnant , breast feeding reproductive age group use medically acceptable form contraception</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Transplant</keyword>
</DOC>